Abeona Q1 net product revenue $8.7M; three ZEVASKYN patients treated; in-licenses PSMA T-cell therapy

ABEONA THERAPEUTICS INC.

2026-Q1 EPS reported -$0.30 revenue$8,720,000

Net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025; net loss $17.1M ($0.30/sh).
Cash and investments $168.3M as of March 31, 2026, down from $191.4M at year-end 2025.
Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites including CHOP and Columbia.
In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; IND expected H2 2027.
Deprioritized in-house ophthalmology programs to focus on ZEVASKYN and ABO-701.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABEONA THERAPEUTICS INC. reported first quarter ended March 31, 2026 results: revenue $8.7 million, net income $(17.1) million, EPS $(0.30) per basic and diluted common share.

Period: first quarter ended March 31, 2026
Revenue: $8.7 million
Net income: $(17.1) million
EPS: $(0.30) per basic and diluted common share
Result: reported results

Exact text from the filing

Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026.

View on SEC.gov

709 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-022610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.